Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2008-06-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 65
- Registration Number
- NCT00417261
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
- Conditions
- Healthy
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00417196
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2010-06-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00416845
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416702
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416728
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00416468
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00416962
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2008-08-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00416546
- Locations
- 🇨🇦
Novartis Investigative Site, Dorval, Quebec, Canada
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00415831
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00415922
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany